CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 52 enrolled
Drug / intervention
nSTRIDE Autologous Protein Solution (APS) Kitdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02610192
NCT02610192N/ACompleted
CompareCT.gov

A Prospective Study of a Single Intra-Articular Injection of Autologous Protein Solution in Females With Primary Patellofemoral Osteoarthritis

Zimmer Biomet·interventional·Posted Nov 20, 2015·Updated Jun 12, 2020

In Brief

A clinical study evaluating nSTRIDE Autologous Protein Solution (APS) Kit for Patellofemoral Osteoarthritis. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate clinical outcomes following a single injection of nSTRIDE Autologous Protein Solution in females with isolated patellofemoral osteoarthritis. A secondary objective of this study is to document the duration of treatment effect following nSTRIDE injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatellofemoral Osteoarthritis
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 20, 2015
Enrollment StartMar 1, 2016
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.6 years ago

Interventions

nSTRIDE Autologous Protein Solution (APS) Kitdevice

Intra-articular injection of APS